Functional single-nucleotide polymorphisms (SNPs) in inositol 1,4,5-trisphosphate 3-kinase C (ITPKC) (rs28493229) and caspase-3 (CASP3) (rs113420705; formerly rs72689236) are associated with susceptibility to Kawasaki's disease (KD). To evaluate the involvement of these 2 SNPs in the risk for intravenous immunoglobulin (IVIG) unresponsiveness, we investigated 204 Japanese KD patients who received a single IVIG dose of 2 g kg À1 (n ¼ 70) or 1 g kg À1 daily for 2 days (n ¼ 134). The susceptibility allele of both SNPs showed a trend of overrepresentation in IVIG non-responders and, in combined analysis of these SNPs, patients with at least 1 susceptible allele at both loci had a higher risk for IVIG unresponsiveness (P ¼ 0.0014). In 335 prospectively collected KD patients who were treated with IVIG (2 g kg À1 ), this 2-locus model showed a more significant association with resistance to initial and additional IVIG (P ¼ 0.011) compared with individual SNPs. We observed a significant association when all KD patients with coronary artery lesions were analyzed with the 2-locus model (P ¼ 0.0031). Our findings strongly suggest the existence of genetic factors affecting patients' responses to treatment and the risk for cardiac complications, and provide clues toward understanding the pathophysiology of KD inflammation.
Introduction
Kawasaki's disease (KD; MIM611775) is an acute febrile illness characterized by high fever, polymorphous skin rash, bilateral conjunctivitis, erythema of the hands and feet, redness of the oral mucosa and cervical lymphadenopathy. 1 Pathologically, KD is a vasculitis of small and medium-sized arteries. 2 Coronary arteries are particularly affected and coronary artery lesions (CALs), such as aneurysms and dilatation, occur in 20-25% of untreated KD patients. 3 KD preferentially affects infants and children younger than 4 years of age and is the leading cause of acquired childhood cardiac disease in developed countries. Although KD has been postulated to be caused by some infectious trigger, the etiology of this disease remains unclear. Intravenous immunoglobulin (IVIG) therapy, introduced in the 1980s, is effective and has reduced the incidence of CAL to o5%; 4 however, around 10-20% of patients are resistant to this treatment and have a higher risk for CAL. [5] [6] [7] [8] Therefore, unraveling the causes of resistance to IVIG and being able to predict patients' responsiveness to IVIG therapy during the early stages of the disease before they develop CAL are urgent clinical issues.
We previously identified 2 susceptibility genes for KD, inositol 1,4,5-trisphosphate 3-kinase C (ITPKC) on 19q13.2 and caspase-3 (CASP3) on 4q34-35 through a genome-wide sib-pair study, followed by linkage disequilibrium mapping and a positional candidate gene study. [9] [10] [11] A functional single-nucleotide polymorphism (SNP) of ITPKC (rs28493229) was associated with KD in Japanese and Caucasian populations. The rs28493229 susceptibility allele also showed a trend of association with developing CAL in both populations and with unresponsiveness to IVIG in the Caucasian population; however, the association of this SNP with unresponsiveness to IVIG in the Japanese population has not been investigated. rs113420705, a functional SNP of CASP3, was also associated with susceptibility to KD in Japanese and Caucasian populations; however, there was no significant association between this SNP and IVIG unresponsiveness or CAL formation. In this study, we investigated the association of these two SNPs and combinations of genotypes with IVIG unresponsiveness and CAL formation in cross-sectional and prospective cohorts of Japanese patients with KD.
Materials and methods

Subjects
All patients were diagnosed as having KD by pediatricians according to previously published criteria. 12 All patients received 2 g kg À1 of IVIG (1 g kg À1 daily for 2 consecutive days or a single dose of 2 g kg À1 ) as an initial treatment. An axillary temperature o37.5 1C that persisted for longer than 24 h was defined as afebrile, and patients who were not afebrile at 24 h after completion of the initial IVIG infusion of 2 g kg À1 in total were considered as IVIG non-responders. CAL formation was evaluated by pediatric cardiologists with two-dimensional echocardiography in accordance with the criteria of the Research Committee on Kawasaki Disease. 13 Dilatations and small aneurysms of coronary arteries that met the criteria, but then regressed within 1 month of illness onset, were excluded from the CAL association study. ) or other antiinflammatory drugs. Patients in this cohort were genotyped for rs28493229 for the first time in this study. On the other hand, of these 204 patients, 200 were included in the 920 KD cases in our previous report of the association between CASP3 SNPs and KD.
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Cohort 2. From April 2008, we conducted a multi-center, prospective trial of cyclosporin A (CsA) for refractory KD. 14 We collected DNA samples from 342 KD patients (male:female ¼ 206:136) enrolled in this cohort. The median age of this cohort was 23.0 months. All patients in this study, except for 7 (4 on the ninth and 3 on the tenth, seventeenth and eighteenth illness days), received an initial dose of IVIG (2 g kg À1 for 24 h) within 8 days of disease onset. These seven patients were included in the association studies for susceptibility to KD, but were excluded from those for IVIG unresponsiveness and CAL formation. In cohort 2, those who were not afebrile at 24 h after the end of the initial IVIG infusion were treated with another 2 g kg À1 of IVIG in 24 h, and the effect of additional IVIG was judged at the end of the treatment.
We collected 947 DNA samples from healthy Japanese controls (male:female ¼ 577:370) from several medical institutes in Japan. All of the patients' parents and healthy volunteers gave written informed consent. This study was approved by the Institutional Review Boards of RIKEN and the other medical institutes participating in this study.
The profiles of participants analyzed in this study are summarized in Table 1 .
Genotyping
We genotyped rs28493229 and rs113420705 by the Invader assay (HOLOGIC, Bedford, MA, USA) as described previously 10, 11 or by direct sequencing.
Statistical analysis
Pearson's w 2 test and logistic regression analysis were used to assess the association between SNPs or genotype combinations and susceptibility to KD and sub-phenotypes of KD, such as unresponsiveness to IVIG and CAL formation. Throughout the study, when performing association studies in the allelic mode, the C allele of rs28493229 and the A allele of rs113420705 were considered as risk alleles. On the other hand, individuals with at least one C allele of rs28493229 or those with at least one A allele of rs113420705 were considered to be at risk in the dominant mode. The ratios of males, IVIG non-responders and KD patients with CAL were compared by Pearson's w 2 test. The mean age at diagnosis and mean days of illness at initial treatment were compared by the Wilcoxon rank-sum test. Pearson's w 2 test was conducted using Microsoft Excel (Microsoft, Redmond, WA, USA), whereas logistic regression analysis and the Wilcoxon rank-sum test were conducted using the R statistical environment version 2.12.2 (R-project; http://www.r-project.org/). Po0.05 was considered as statistically significant.
Results
Association of rs28493229 and rs113420705 with KD Frequencies of the susceptibility allele (C) at rs28493229 in the combined cohorts and healthy controls were 22.1 and 15.5%, respectively (P ¼ 7.1 Â 10 À6 and P ¼ 6.3 Â 10 À5 for allele frequency comparison and dominant inheritance model, respectively; Supplementary Table 1) . As the majority of KD patients in cohort 1 and 378 of controls were included as subjects in our previous CASP3 study, 11 we assessed the association of rs113420705 with KD in cohort 2 and 566 controls. In this case-control set, the susceptibility allele of rs113420705 (A) was significantly overrepresented in KD cases (41.5%) than in controls (36.1%) (P ¼ 0.022 and P ¼ 0.016 for allele frequency comparison and dominant inheritance model, respectively; Supplementary Table 2) . Thus, the previously reported associations of rs28493229 and rs113420705 with KD susceptibility were validated in independent Japanese KD cases and controls.
Association of rs28493229 with IVIG unresponsiveness
We compared the allele and genotype frequencies of rs28493229 in IVIG responders and non-responders in cohort 1. Regardless of the regimen of IVIG treatment (1 g kg À1 daily in 2 consecutive days or a single dose of 2 g kg À1 of IVIG), the prevalence of the rs28493229 C allele was higher in IVIG non-responders, and the difference was significant when both groups were combined (P ¼ 0.0099 and P ¼ 0.015 for allele frequency comparison and dominant inheritance model, respectively; Tables 2 and 3 ). In cohort 2, patients were classified into the 3 following groups: first IVIG responders, second IVIG responders and second IVIG non-responders. Although we observed a trend for the overrepresentation of the C allele in IVIG non-responders, the difference was not significant (Tables 2 and 3) .
Association of rs113420705 with IVIG unresponsiveness
The majority of patients in cohort 1 were analyzed in our previous study of the association of rs113420705 with susceptibility to KD. 11 A trend of overrepresentation of the susceptibility allele (A) in IVIG non-responders was observed in this cohort; however, as described in our previous report, it was not significant (Tables 3 and 4) . In cohort 2, a significant association was observed between unresponsiveness to the second IVIG treatment and the susceptibility allele in a dominant inheritance mode (odds ratio (OR) ¼ 2.95, 95% confidence interval (95% CI) ¼ 1.10-7.91; P ¼ 0.031; Tables 3 and 4) .
Two-locus association model
Although both functional SNPs of the ITPKC and CASP3 genes were plausibly relevant to IVIG resistance, the trend was modest; therefore, we investigated the combinatorial effect of these two SNPs. We considered 12 combinatorial patterns (Supplementary Figure 1 ) and performed association studies within cohort 1. As a result, the most significant association was observed in one model in which heterozygosity or homozygosity of the susceptibility allele at both SNPs increased the risk. As shown in Table 5 , a higher fraction of IVIG non-responders carried risk alleles at both loci and the association was more significant than for the individual SNPs (OR ¼ 2.90, 95% CI ¼ 1.51-5.58; P ¼ 0.0014). This association was significant even after correction for multiple testing (n ¼ 12; corrected P ¼ 0.017). Consistent with this observation, we obtained a higher OR and lower P-value than for the individual SNPs in this 2-locus association model for comparison of KD patients who responded to either the first or second IVIG treatment and those resistant to the first and second IVIG treatments in cohort 2 (OR ¼ 2.65, 95% CI ¼ 1.25-5.62; P ¼ 0.011). Thus, patients who had risk alleles at both SNPs were at a higher risk for IVIG resistance in both cohorts, and this observation was further reinforced by a more significant association in the combined analysis of both cohorts (OR ¼ 2.79, 95% CI ¼ 1.71-4.57; P ¼ 0.000042). As the P-value for the 2-locus interaction term was the lowest in a logistic regression analysis in which rs28493229 and rs113420705 were taken into account as covariates (Supplementary Table 3 ), we considered that the model explains the involvement of these two loci in determining the IVIG responsiveness of KD patients better than the individual SNPs.
Association with CAL formation
In cohorts 1 and 2, 24 and 6 patients, respectively, developed CAL. In both cohorts, the rs28493229 C allele tended to be overrepresented in these patients (Table 2) , and this association was significant in the combined analysis (dominant model, OR ¼ 2.87, 95% CI ¼ 1.29-6.40; P ¼ 0.0098). The rs113420705 A allele also showed a trend of association with CAL formation in the combined analysis; however, it was not statistically significant (dominant model, OR ¼ 1.62, 95% CI ¼ 0.68-3.89; P ¼ 0.28). When all patients were analyzed together in the 2-locus model, a more significant association was observed (OR ¼ 3.30, 95% CI ¼ 1.50-7.30; P ¼ 0.0031) compared with analysis of the individual SNPs (Table 6 ).
Discussion
High-dose IVIG is the standard therapy for KD; however, it has been reported that 10-20% of patients are resistant to this treatment and have a higher risk for CAL formation. [5] [6] [7] [8] How to predict patients' responsiveness to IVIG and how to treat them with additional therapies are the most important issues in this disease. Several risk-scoring systems have been developed using age, day of starting initial treatment and laboratory data; [15] [16] [17] however, even using these systems, 420% of IVIG non-responders cannot be predicted. One of the reasons why it is so difficult to make an accurate prediction might be the presence of a yet-to-be-clarified mechanism of IVIG action on KD inflammation. In a Japanese literature reviewing the data of past nationwide surveys, the authors described that the lethality rate among sibling cases of KD was three times higher than usual. 18 Taking the fact that sibling cases are likely to share common genetic factors for KD susceptibility into account, the data suggest that some of the susceptibility variants also confer more severe clinical manifestations. Furthermore, rates of IVIG non-responders or CAL formation differ among reports from different ethnic groups. [5] [6] [7] [8] 19, 20 Thus, some host genetic factors must influence the clinical severity of KD. Many researchers who recognize this issue have repeatedly examined the association of candidate genetic variations with CAL formation and IVIG unresponsiveness. 21 In this exploratory analysis, we demonstrated that alleles or genotypes of ITPKC and CASP3 confer increased risks for IVIG unresponsiveness and CAL formation. During the preparation of this manuscript, the association of the rs28493229 C allele with KD was confirmed in a metaanalysis of three case-control studies in the Taiwanese population. 22 A marginal association of the rs113420705 A allele with KD was also reported by the same group. 23 Interestingly, in the Taiwanese population studied in these articles, both risk alleles were also associated with CAL formation in a recessive model. Although the mode of association differs (2-locus combination in the Japanese population versus recessive in the Taiwanese population), it is likely that variations of ITPKC and CASP3 confer susceptibility to KD and CAL formation in different ethnic groups.
Certain limitations to this study should be noted. First, the association of the 2-locus model with unresponsiveness to the first IVIG in cohort 2 was relatively weak. Although Patients who received their initial IVIG on the ninth day of illness or later were excluded.
ITPKC and CASP3 polymorphisms confer severity of KD Y Onouchi et al both risk alleles tended to be overrepresented in nonresponders to the first IVIG in cohort 2 and this trend was also seen in the 2-locus model (OR ¼ 1.12-1.29), the trend appeared to be driven by non-responders to the second IVIG because an association was not seen between the first and second IVIG responders (Supplementary Table 4 ). We speculated that there were some cases in cohort 1 with a disease severity comparable to that of the second IVIG nonresponders in cohort 2 on the basis of the fact that the two participating hospitals were flagship medical centers that were treating KD patients who failed to respond to initial or additional IVIG at subsidiary hospitals. On the other hand, patients in cohort 2 were participants of a prospective clinical trial in which both types of hospitals participated; therefore, those who responded or responded poorly to IVIG therapy were enrolled with a small bias. Although a simple comparison of the prevalence of CAL between the two cohorts could be erroneous because of the different treatment strategies, the higher prevalence of CAL in cohort 1 (25 out of 204; 12.3%) than in cohort 2 (6 out of 335; 1.8%) Adjusted for gender and age. e IVIG responders in cohort 1 and first or second IVIG responders in cohort 2 were combined. f IVIG non-responders in cohort 1 and 2nd IVIG non-responders in cohort 2 were combined. The underlined alleles were the minor and at risk alleles. Association was evaluated under a dominant inheritance model of the risk alleles.
b KD patients with the GG genotype and those with the GC or CC genotypes were classified into low-and high-risk groups, respectively. c KD patients with the GG genotype and those with the GA or AA genotypes were classified into low-and high-risk groups, respectively. might support the above speculation. Second, the regimen of IVIG in cohort 1 was not unified. It is possible that the association of the two alleles with the risk for IVIG unresponsiveness and CAL formation was confounded by the difference in the initial dose of IVIG. However, we consider that this may not have profoundly affected our conclusion because the combinatorial effect of the two alleles was also observed when both patient groups with different IVIG regimens were analyzed separately and the results of the combined analysis were significant after adjustment for the differences in IVIG doses ( Table 6 ) were still significant. The time point used to assess the efficacy of IVIG is another critical factor affecting the diagnosis of non-responders. An early judgment might lead to overdiagnosis, whereas a late judgment might increase the risk for CAL formation. We defined those who were not afebrile at 24 h after completion of a total of 2 g kg À1 IVIG in both cohorts as IVIG non-responders in this study. However, as a consequence of the different times required for infusion (48 h for those treated with 1 g kg À1 IVIG over 2 consecutive days and 24 h for those treated with a single infusion of 2 g kg À1 IVIG), the criteria were still different in terms of the time from the start of treatment. The results might change if the judgment was made at a different time point or if IVIG infusion was conducted more rapidly as in the United States or other countries (in 10-12 h). Third, administration of CsA might affect the prevalence of CAL in cohort 2. Of the 32 patients who did not respond to the double administration of IVIG in cohort 2, 28 received CsA and 4 were treated with additional IVIG (2 g kg À1 ). CAL developed in four of those treated with CsA, including two in whom CAL had already formed during the period when they were receiving IVIG. Two patients had CAL before they became afebrile after the completion of the second or third IVIG. As our trial of CsA was not randomized and the number of patients was limited, we could not assess the relative advantage of using CsA to prevent CAL, as well as its confounding effect on this study. Finally, we did not assess the influence of the brands and lots of immunoglobulin products on patients' responses or the coronary artery outcome. However, it has been reported that there is no significant difference in efficacy and safety among the different brands of immunoglobulins with three different viral-inactivation steps, sulfonation, polyethylene glycol treatment and acid treatment (pH 4) that were used to treat patients in this study. 24 In this study, we found that there was a combinatorial effect between the rs28493229 C allele and rs113420705 A allele. The advantage of analyzing a 2-locus association model is that it is easier to detect an association even when the number of subjects is not so large and the contribution of each locus is relatively weak. However, as documented in a recent large meta-analysis of genome-wide association studies for Crohn's disease, 25 the interaction of common susceptibility loci is not usually observed. In addition, testing various patterns of combinations increases the incidence of a type one error; hence, correction of the statistical values for multiple testing should be considered. Therefore, we cannot always expect favorable results in such analyses. Conversely, when epistasis or combinatorial effects of variations are observed, the possible involvement of a certain pathway in which both molecules have roles or of direct and indirect interactions between the two molecules in disease pathogenesis would become strongly suggestive and arouse interest.
Inositol 1,4,5-trisphosphate 3-kinase C negatively regulates the activation of NFAT (nuclear factor of activated T cells) by phosphorylating inositol trisphosphate, the second messenger molecule of various cell types. 5 As it has been reported that CASP3 cleaves NFATc2 as one of its substrates in T cells, 26 we speculate that CASP3 may also act as a negative regulator of the Ca 2 þ /NFAT pathway. In addition, we suppose that the decreased activity of ITPKC and CASP3 may lead to overproduction of downstream molecules of this pathway and might be related to hyperactivation of the immune system. Furthermore, the C allele of rs28493229 and the A allele of rs113420705 may both increase the severity of inflammation, thereby promoting progression to KD and, once affected, more severe inflammation could result in unresponsiveness to IVIG and the development of CAL.
The combinatorial effect of both risk alleles observed in this study might corroborate our hypothesis that ITPKC and CASP3 have roles in the regulation of the Ca 2 þ /NFAT pathway. Resistance to 2 courses of 2 g kg À1 IVIG, a subphenotype of KD associated with the SNPs in cohort 2, is an indication that patients are at a high risk for CAL formation and require the immediate resolution of inflammation by administration of additional IVIG or alternative drugs because the mean day of illness when CAL start to develop (day 10) 27 is approaching or has gone. Our present data suggest the possibility that such a high-risk trait is, at least partly, determined by genetic components. Individual SNPs and the combination of genotypes in this study were not so powerful as predictors of IVIG resistance or CAL formation in terms of their sensitivity and specificity (Supplementary Figure 1, Table 6 ); however, it is also true that there is room for improvement in the current risk-scoring systems, and genetic markers could be considered as additional parameters. We are currently evaluating the association between the SNPs used in this study and known clinical parameters that are relevant to IVIG resistance.
In summary, we successfully replicated the association of the functional SNPs of ITPKC and CASP3 with susceptibility to KD and found that these SNPs cooperatively affect the severity of KD in the Japanese population. To our knowledge, these are the first genetic factors for the severity of KD that have been confirmed prospectively. Further identification of such genetic markers may promote the understanding of the mechanism of IVIG action and pave the way for personalized medicine.
